LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Pharma has been recognised for its excellence in innovation by the leading UK life sciences body Medilink UK. Dr Faz Chowdhury received the award on behalf of the company at a ceremony in Coventry on Wednesday 25th April. Nemaura had previously won the Medilink East Midlands award for Innovation, and faced strong competition from other UK biotechnology businesses.
In its submission, Nemaura cited the design and development of the Micro-Patch™, a low-cost, disposable drug delivery device which deposits a solid dose under the skin. Trials have shown Micro-Patch™ to be a highly consistent and effective method of delivering drugs such as vaccines.
Dr Chowdhury said: “I want to acknowledge the expertise and scientific brilliance of all my colleagues in accepting this award. We appreciate the accolade given by industry peers and by Medilink UK which is extremely valuable as we continue to grow and bring new innovations to market.”
This timely announcement coincides with World Immunization Week, an annual campaign run by the World Health Organisation (WHO) to highlight the importance of continuing funding and delivery of vaccines programmes to the world’s most vulnerable populations. The message to leading research and development organisations such as Nemaura is that it is vital to continue to invest in new technologies which will have a long-term impact.
Dr Chowdhury continues: “Vaccines are one of the most cost-effective health tools ever invented. So our work in advancing the use of the solid dose form, eliminating the need for cold chain transport and storage, will contribute to drive down costs. We are committed to working with global partners to bring the Micro-Patch™ technology to market, and to playing our part in the wider WHO goal of eradicating common diseases.”
About Nemaura Pharma
Founded in 2005, Nemaura Pharma is a private specialist biotech company with headquarters and research facilities in the Advanced Technology Centre on the Loughborough University Science and Enterprise Park (LUSEP) in the United Kingdom.
The company employs multi-disciplinary teams of scientists and engineers working in innovative drug formulation and medical device technologies designed to radically improve the way drugs are administered through the skin. It has patents secured or pending in multiple countries across numerous patent families.
About World Health Organisation #VaccinesWork campaign
Cautionary Statement Regarding Forward-Looking
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.